Role of aldosterone in the remnant kidney model in the rat

E L Greene, S Kren, T H Hostetter, E L Greene, S Kren, T H Hostetter

Abstract

The renin-angiotensin-aldosterone system (RAAS) participates in the injury sustained by the remnant kidney. Our studies assessed the importance of aldosterone in that model and the response of aldosterone to drugs interfering with the RAAS. Initially, four groups of rats were studied: SHAM-operated rats, untreated remnant rats (REM), REM rats treated with losartan and enalapril (REM AIIA), and REM AIIA rats infused with exogenous aldosterone (REM AIIA + ALDO). The last group was maintained with aldosterone levels comparable to those in untreated REM rats by constant infusion of exogenous aldosterone. REM rats had larger adrenal glands and a > 10-fold elevation in plasma aldosterone compared to SHAM. REM AIIA rats demonstrated significant suppression of the hyperaldosteronism as well as marked attenuation of proteinuria, hypertension, and glomerulosclerosis compared to REM. REM AIIA + ALDO rats manifested greater proteinuria, hypertension, and glomerulosclerosis than REM AIIA rats. Indeed, by 4 wk of observation all of these features of the experimental disease were similar in magnitude in REM AIIA + ALDO and untreated REM. In separate REM rats spironolactone administration did not reduce glomerular sclerosis but did transiently reduce proteinuria, lowered arterial pressure, and lessened cardiac hypertrophy. In summary, aldosterone contributes to hypertension and renal injury in the remnant kidney model.

References

    1. Hypertension. 1982 Mar-Apr;4(2):279-87
    1. Lab Invest. 1962 Apr;11:321-32
    1. Am J Kidney Dis. 1993 Jul;22(1):164-73
    1. Am J Physiol. 1992 Nov;263(5 Pt 1):E974-9
    1. Diabetes. 1994 Jan;43(1):95-103
    1. J Clin Invest. 1988 Jan;81(1):69-74
    1. Hypertension. 1992 Jul;20(1):67-73
    1. J Clin Invest. 1992 Sep;90(3):766-71
    1. J Lab Clin Med. 1992 Dec;120(6):893-901
    1. Hypertension. 1990 Jan;15(1):78-83
    1. Kidney Int. 1992 Jun;41(6):1527-34
    1. Am J Physiol. 1991 May;260(5 Pt 1):E719-26
    1. Kidney Int. 1982 Jan;21(1):98-101
    1. Kidney Int. 1976 May;9(5):407-17
    1. J Clin Invest. 1984 May;73(5):1448-61
    1. Hypertension. 1979 May-Jun;1(3):331-6
    1. Cardiovasc Drugs Ther. 1995 Feb;9(1):145-9
    1. J Clin Invest. 1986 Jun;77(6):1993-2000
    1. Physiol Rev. 1992 Jan;72(1):231-300
    1. Kidney Int. 1983 Sep;24(3):386-91
    1. Am J Physiol. 1990 May;258(5 Pt 2):F1409-16
    1. Am J Physiol. 1993 May;264(5 Pt 2):F781-91
    1. Hypertension. 1993 Mar;21(3):294-300
    1. Kidney Int. 1994 Feb;45(2):403-10
    1. Hypertension. 1986 Nov;8(11):997-1002
    1. J Clin Invest. 1994 Jun;93(6):2578-83
    1. Am J Kidney Dis. 1989 Feb;13(2):120-6
    1. Kidney Int. 1992 Feb;41(2):326-33
    1. Kidney Int. 1978 Sep;14(3):228-35
    1. Kidney Int. 1984 Feb;25(2):376-82
    1. Arch Intern Med. 1986 Nov;146(11):2145-8
    1. N Engl J Med. 1993 Nov 11;329(20):1456-62

Source: PubMed

3
Abonneren